A sketch of known and novel MYCN-associated miRNA networks in neuroblastoma

FRANCESCA MEGIORNI1, MORENO COLAIACOVO2*, SAMANTHA CIALFI3, HEATHER P. MCDOWELL1,4, ALESSANDRO GUFFANTI2, SIMONA CAMERO1, ARMANDO FELSANI2, PAUL D. LOSTY5,6, BARRY PIZER4, RAJEV SHUKLA7, CARLO CAPPELLI1, EVA FERRARA1, ANTONIO PIZZUTI8, ANNA MOLES2,9 and CARLO DOMINICI1

1Department of Paediatrics and Infantile Neuropsychiatry, Sapienza University of Rome, I-00161 Rome; 2Genomnia s.r.l., I-20091 Bresso, MI; 3Department of Molecular Medicine, Sapienza University of Rome, I-00161 Rome, Italy; Departments of 4Oncology, and 5Paediatric Surgery, Alder Hey Children’s NHS Foundation Trust, L12 2AP Liverpool; 6Academic Paediatric Surgery Unit, University of Liverpool, L12 2AP Liverpool; 7Department of Perinatal and Paediatric Pathology, Alder Hey Children’s NHS Foundation Trust, L12 2AP Liverpool, UK; 8Department of Experimental Medicine, Sapienza University of Rome, I-00161 Rome; 9Institute of Cell Biology and Neurobiology CNR, I-00143 Rome, Italy

Received September 8, 2016; Accepted April 27, 2017

DOI: 10.3892/or.2017.5701

Abstract. Neuroblastoma (NB) originates from neural crest-derived precursors and represents the most common childhood extracranial solid tumour. MicroRNAs (miRNAs), a class of small non-coding RNAs that participate in a wide variety of biological processes by regulating gene expression, appear to play an essential role within the NB context. High-throughput next generation sequencing (NGS) was applied to study the miRNA transcriptome in a cohort of NB tumours with and without MYCN-amplification (MNA and MNnA, respectively) and in dorsal root ganglia (DRG), as a control. Out of the 128 miRNAs differentially expressed in the NB vs. DRG comparison, 47 were expressed at higher levels, while 81 were expressed at lower levels in the NB tumours. We also found that 23 miRNAs were differentially expressed in NB with or without MYCN-amplification, with 17 miRNAs being upregulated and 6 being downregulated in the MNA subtypes. Functional annotation analysis of the target genes of these differentially expressed miRNAs demonstrated that many miRNAs were involved in cancer-related pathways, such as DNA-repair and apoptosis as well as FGFR and EGFR signalling. In particular, we found that miR-628-3p negatively affects MYCN gene expression. Furthermore, we identified a novel miRNA candidate with variable expression in MNA vs. MNnA tumours, whose putative target genes are implicated in the mTOR pathway. The present study provides further insight into the molecular mechanisms that correlate miRNA dysregulation to NB development and progression.

Introduction

Neuroblastoma (NB) is a paediatric solid tumour arising from neural crest-derived precursors, and it accounts for 8-10% of all malignancies and 12-15% of cancer-related deaths in children (1). It is characterized by marked clinical heterogeneity, and the assessment of NB-related genetic abnormalities has been helpful in predicting clinical outcome, stratifying patients into different risk classes and designing appropriate treatments (2,3). MYCN amplification at 2p24 is a well-known genetic alteration associated with NB development and progression (4-8), irrespective of age at diagnosis and clinical stage, whose examination is required in NB tumours before treatment begins (9). Indeed, approximately half of high-risk aggressive tumours are characterized by amplification of the MYCN gene, an oncogene of the MYC family of transcription factors that controls the expression of many target genes, which in turn regulates fundamental cellular processes including proliferation, cell growth, apoptosis and differentiation (10).

MicroRNAs (miRNAs) are a class of small non-coding RNAs that regulate gene expression at the post-transcriptional level, by binding to the complementary sites in the 3’-untranslated region (3’-UTR) of target messenger RNAs (11-13). Currently, more than 1,800 miRNA genes have been identified in the human genome (miRBase release 21.0) (14), and bioinformatic predictions indicate that up to 60% of protein-coding genes may be regulated by miRNAs (15). miRNAs play a central role in many cellular processes and their aberrant expression has been reported in childhood solid tumours, including NB (16,17). In the latter, by applying miRNA microarrays and high-throughput sequencing technologies, a series
of miRNAs have been reported to play a role as oncogenes or tumour suppressors, as reviewed by Mei et al (18). For example, dysregulation of miR-542-5p is highly correlated with tumour aggressiveness and poor survival (19), while miRNA-34a was found to be a potent tumour-suppressor molecule (20). Moreover, some miRNA levels appear to have the potential to increase the efficacy of treatment by regulating the sensitivity of NB cells to cisplatin (21,22).

In the present study, we investigated the expression of miRNAs in NB by using next generation sequencing (NGS) technology, which allows for a comprehensive assessment of the miRNA transcriptome and has the potential to detect miRNA length variations or sequence modifications (iso-miRs) as well as novel miRNA sequences. The SOLiD System was used to sequence small RNA (sRNA) libraries from NB tumours with and without MYCN-amplification and from human dorsal root ganglia (DRG) as a control, in order to detect the genome-wide differences in miRNA levels in these two subtypes of NB. The analysis showed that 128 known miRNAs were significantly dysregulated in the NB tumours in comparison to DRG, utilised as a normal control. Notably, 23 miRNAs were differentially expressed in MYCN-amplified vs. MYCN-non amplified tumours. Furthermore, 18 new miRNA candidates were detected in NB samples: 10 in the MNA, 6 in the MNnA samples and 2 in both tumour subtypes; 2 putative novel miRNAs were found in the DRG. Notably, the Gene Ontology (GO) analysis of the potential targets of the upregulated and downregulated miRNAs indicated that many genes belong to biological processes and cellular components that are involved in cell growth, cell shape, protein activity and genomic instability necessary for cancer initiation and progression. Furthermore, analysis with Kyoto Encyclopedia of Genes and Genomes (KEGG) web tools revealed significant enrichment in several cancer-related signalling pathways.

The present study provides valuable information concerning the mechanisms in NB of the miRNA-associated MYCN network that may contribute to the development of novel diagnostic biomarkers and effective therapeutic strategies for this cancer.

Materials and methods

Patient features and normal controls. Twenty-two NB primary tumour samples, equally distributed between MYCN-amplified (MNA) and MYCN-non amplified (MNnA) samples, were obtained at diagnosis before any treatment from children admitted to the Department of Oncology at Alder Hey Children's NHS Trust, Liverpool. Histopathological diagnosis was confirmed using immunohistochemistry. Details of the patients are described in Table I. Institutional written informed consent was obtained from the patient's parents or legal guardians.

The study underwent ethical review and approval according to the local institutional guidelines (Alder Hey Children's NHS Foundation Trust Ethics Committee, approval number 09/H1002/88).

Human DRG total RNA (Clontech Laboratories, Inc., Mountain View, CA, USA), pooled from normal tissues of 21 male/female Caucasians who had died suddenly, was used as a normal control. DRG were utilised as a normal control because

| Case | Age at diagnosis | MYCN status | Primary site | Clinical stage |
|------|-----------------|-------------|--------------|---------------|
| NB1a | 36              | <3          | Adrenal      | 4             |
| NB2a | 65              | <3          | Adrenal      | 4             |
| NB3a | 69              | <3          | Adrenal      | 4             |
| NB4a | 53              | <3          | Abdomen      | 4             |
| NB22 | 199             | <3          | Abdomen      | 4             |
| NB45 | 3               | <3          | Abdomen      | 4             |
| NB54 | 6               | <3          | Adrenal      | 4             |
| NB70 | 22              | <3          | Abdomen      | 4             |
| NB80 | 25              | <3          | Abdomen      | 4             |
| NB96 | 111             | <3          | Adrenal      | 4             |
| NB106| 7               | <3          | Thorax       | 2             |
| NB5* | 10              | >10         | Adrenal      | 4             |
| NB6* | 8               | >10         | Adrenal      | 4             |
| NB7* | 37              | >10         | Adrenal      | 4             |
| NB8* | 16              | >10         | Abdomen      | 4             |
| NB57 | 44              | >10         | Adrenal      | 2             |
| NB68 | 13              | >10         | Abdomen      | 4             |
| NB79 | 29              | >10         | Abdomen      | 4             |
| NB81 | 37              | >10         | Adrenal      | 2B            |
| NB97 | 40              | >10         | Abdomen      | 4             |
| NB100| 179             | >10         | Abdomen      | 4             |
| NB105| 16              | >10         | Adrenal      | 4             |

Variables were categorized as follows: age at diagnosis (months), MYCN-amplification status, primary site and clinical stage. MYCN-amplified >10; MYCN-non amplified <3. *Samples used for deep sequencing analysis.

RNA isolation. Tumour samples were frozen in liquid nitrogen immediately after surgical removal and stored at -80°C. Total RNA was isolated by tissues ground under liquid nitrogen using 1 ml of TRIzol LS reagent (Life Technologies, Carlsbad, CA, USA) per 50-100 mg of sample according to the manufacturer's protocol. RNA concentration and purity were measured by NanoDrop 2000 (Thermo Fisher Scientific, Inc., Waltham, MA, USA), having 260/280 ratio values in the range of 1.9-2.1.

Small RNA library construction and high-throughput sequencing. Total RNA samples (5 µg) were enriched for small RNAs up to 200 bp by size selection using PureLink miRNA Isolation kit (Life Technologies) and RNA quality was assessed, before and after RNA enrichment, by the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) using a Agilent RNA 6000 Nano and a Agilent Small RNA kit, respectively. Enriched RNA samples were processed using the Small RNA Expression kit according to the manufacturer's protocol (Small RNA Expression kit, rev.

Table I. Clinicopathological features of the analysed tumour cases.
B; Applied Biosystems, Foster City, CA, USA). Briefly, 20 ng of RNA was first hybridized and ligated with the adapter mix ‘A’, subsequently reverse transcribed and treated with RNase H. The cDNA libraries were then PCR amplified, purified and size-selected by PAGE, resulting in libraries containing inserted small RNA sequences of 20-40 bp length. Size, integrity and purity of the libraries were verified by the Agilent 2100 Bioanalyzer, Agilent DNA 1000 Kit. The cDNA libraries were barcoded using the SOLiD RNA barcoding kit and amplified onto beads using emulsion PCR. Templated beads were deposited on slides and analysed using the Applied Biosystems SOLiD 4 sequencer.

Quantification of known microRNAs. The qualified clean reads were mapped and analysed with the ‘small RNA’ bioinformatics pipeline from the Thermo Fisher LifeScope version 2.5.1 software (https://www.thermofisher.com/it/en/home/technical-resources/software-downloads/lifescope-genomic-analysis-software.html), using as a target the human genome GRCh38/hg38 and the dataset of mature and precursor miRNA sequences (miRBase, release 21.0) (25). Any sequence match against repetitive elements of the genome (SINEs and LINEs), and against non-miRNA small RNAs (snoRNAs, piRNAs, tRNAs and RNA fragments) were filtered out from the results. Sequences counts were extracted and reformatted with Genomnia Perl scripts from the pipeline output. Differential expression analysis was performed with the edgeR Bioconductor statistical library version 3.1.0 on R (26) incorporated in a proprietary Genomnia pipeline. TMM-normalized sequence counts in the libraries were transformed in counts per millions (CPM) according to the formula: CPM = (transcript normalized counts/total miRNA matches) x 1,000,000. After having estimated the tagwise dispersion, genewise exact test (26) as implemented in edgeR was used to measure the differential expression of known microRNAs. miRNA assays (Life Technologies) specific for human miR-18a-5p, miR-217, miR-491-5p and miR-628-3p, according to the manufacturer’s protocol. Ct values for miRNAs was calculated by the comparative Ct method and expressed as an internal control. The relative expression of each miRNA normalized against U6 small nuclear RNA (RNU6) levels, used to the Benjamini-Hochberg procedure (SD), and a P-value corrected for multiple comparison with the Benjamini-Hochberg procedure) obtained with this method was <0.05. The MNA vs. MNNa comparison was also performed with the edgeR generalized linear model (GLM) mode optimised for the analysis of data with sequence spikes (27), in order to confirm the obtained results with a second robust statistical approach well suited to handle outlier data.

miRNA target prediction, functional annotation and promoter motif discovery. For each differentially expressed miRNA, a list of experimentally validated targets was extracted from miRTarBase release 6 (http://mirtarbase.mbc.nctu.edu.tw/) (28). In addition, de novo target prediction was performed using the miRanda software (29) on selected downregulated and upregulated microRNAs from the comparison MNA vs. MNNa. The 3’UTR sequences of all human transcripts present in Ensembl (release 78) were used as a target set for this analysis, and only predictions with total score ≥155 and total energy ≤-20 were considered as putative miRNA targets. Annotation and enrichment of functional pathways and ontology terms associated with the selected target genes were evaluated using DAVID Bioinformatics Resources 6.7 (30). The same target gene list was used as the starting dataset for the generation of a Functional Interaction network analysis and related Gene Ontology enrichment analysis with the Cytoscape Reactome Fi plugin (31,32). Promoter regions of the differentially expressed miRNAs in the comparison MNA vs. MNNa were scanned for motifs by FIMO 4.10.2 software (http://meme-suite.org/tools/fimo) (33). A sequence of 5 Kb was considered as putative upstream regulatory region for each miRNA or miRNA cluster based on the histone acetylation track (H3K27Ac) reported in UCSC. Finally, the MYCN binding motifs available in JASPAR CORE database (http://jaspar.genereg.net/) were used in the promoter analysis.

Identification of isomiRs and prediction of novel microRNAs. The alignment files in BAM format corresponding to the same biological group (MNA, MNNa and Control) were merged and converted to sequence alignment/map (SAM) format with samtools (34). The files were then processed and analysed with the miRDeep2 software for miRNA prediction (35). The differential expression analysis for isomiRs was carried out with edgeR from Bioconductor, with the same analytical strategy previously described. A set of potentially novel microRNAs was also identified, by selecting among miRDeep2 predictions the hairpins with a probability >60% to be a true positive. Their expression was also evaluated in all samples. miRNA extraction, library preparation, sequencing and bioinformatics analysis were performed by Genomnia s.r.l.

Quantitative real-time PCR (qPCR). Quantitative real-time PCR (qPCR) was performed to validate some results obtained from the high-throughput sequencing. In brief, step-loop reverse transcription and qPCR were carried out using TaqMan MicroRNA assays (Life Technologies) specific for human miR-18a-5p, miR-217, miR-491-5p and miR-628-3p, according to the manufacturer’s protocol. Ct values for miRNAs was normalized against U6 small nuclear RNA (RNU6) levels, used as an internal control. The relative expression of each miRNA was calculated by the comparative Ct method and expressed as fold-change. All samples were run in triplicate reactions in the StepOnePlus Real-Time system (Life Technologies) instrument. Results are expressed as means ± standard deviation (SD), and a P<0.05 was considered statistically significant.

Cell lines. The MYCN-amplified KCN cell line was grown in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% v/v non-essential amino acid solution, 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. HEK (human embryonic kidney) 293T cells were cultured in high-glucose DMEM, supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. All cell lines were maintained in a humidified incubator at 37°C and 5% CO₂, and appropriately sub-cultured before confluence was reached.

Plasmid construction and luciferase assays. The 3’UTR region of the human MYCN gene (3HSAR055440 derived from http://utrdb.ba.itb.cnr.it/) was amplified from genomic DNA using a proof reading Phusion High-Fidelity PCR Master Mix (Finzymes, Espoo, Finland) with the following primers:
MYCN 3'UTR-F 5'-GCTCTAGAACGCTTCTCAAACTG
GACAGTCAC-3' and MYCN 3'UTR-R 5'-GCTCTAGAAA
CATGAGGTATTTCAAGTCTATAAGATGC-3'. The
880-bp amplified product was inserted into the
XbaI site (underlined primer sequences) of the pRLTK vector (Promega, Madison, WI, USA) immediately downstream of the Renilla luciferase gene. The luciferase reporter construct, termed pMYCN-3'UTR, was validated by specific restriction digests as well as bi-directional sequencing by Bio-Fab Research (Rome, Italy). HEK293T cells were plated at a density of 1.5x10^5/well in 24-well plates and co-transfected after 24 h with 50 ng of pMYCN-3'UTR Renilla luciferase construct, 10 ng of reference firefly luciferase reporter (pGL3-SV40; Promega) and 100 nM of mir-628-3p (mirVana miRNA mimic - MI0003642/MIMAT0003297 by Thermo Fisher Scientific) or miR-Ctr (miRIDIAN microRNA Mimic Negative Control #1; Dharmacon, Lafayette, CO, USA) molecules using 2 µl of Lipofectamine 2000 (Invitrogen). Cells were lysed 72 h after transfection and luciferase signals were detected by the Dual-luciferase reporter assay (Promega) using the GloMax Discover System (Promega), following the manufacturer's instructions. Renilla luciferase activity was normalized to the firefly luciferase activity for each reaction. Two independent experiments were carried out, each in triplicate. All the luciferase data are expressed as the mean ± SD normalized to the negative control miRNA.

Protein extracts and western blot analysis. KCNR cells were seeded at 6.0x10^5/well in 12-well plates and transfected the day after with miR-628-3p or miR-Ctr (50 mM final concentration) using Lipofectamine 2000, according to the manufacturer's instructions. After 72 h, protein expression was determined by western blotting as previously described (36) with a primary antibodies against MYCN (1:1,000; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Tubulin (Sigma-Aldrich, St. Louis, MO, USA) was used as a normalization control for equal loading. Chemiluminescent signals were revealed by ChemiDoc XRS+ System (Bio-Rad Laboratories, Hercules, CA, USA) and densitometric analysis was performed by Image Lab 5.1 software (Bio-Rad Laboratories).

Results and Discussion

Identification and quantification of annotated miRNAs. Comprehensive miRNA, isomiR and novel miRNA identification, annotation and analysis were developed in the framework of this project and are summarized in Fig. 1. The miRNA transcriptome was profiled by sequencing of mature miRNA molecules in a panel of primary NB tumours, 4 with MYCN-amplification (MNA) and 4 without MYCN-amplification (MNnA) and from normal dorsal root ganglia (DRG). The clinical characteristics of the patients are reported in Table I. Small RNA libraries were prepared and deep sequenced by using a SOLiD 4 sequencer platform. Approximately 71 million reads mapped with high quality against the human reference genome (GRCh38/hg38, repeat masked), with an average of 8 million reads per library. The reads corresponding to annotated miRNAs were identified by mapping all reads against the human precursor and mature sequences included in miRBase v21.0. Fig. 2A shows that a total of 532 distinct known miRNAs had on average at least 10 read counts in the NB tumour samples, while 512 miRNAs were detected in the DRG sample; 382 of these were expressed in both conditions, with a 72% overlap for NB miRNAs and 75% overlap for DRG miRNAs. Thus, about a quarter of the identified known microRNAs were uniquely expressed in NB or control samples. NB-specific miRNAs might therefore play an important functional role in tumour development and progression, through the regulation of downstream targets and the biological pathways affected by these genes.

Differential expression analysis of miRNAs in NB vs. DRG and functional annotation analysis. Based on the high-throughput sequencing of small RNAs, we performed differential expression analysis of miRNAs comparing the two libraries from NB tumours (MNA and MNnA collec-
### Table II. miRNA expression in NB tumours.

#### A, miRNA species expressed at higher levels in NBs (MNA and MNnA are collectively considered) vs. DRG

| miRNA_ID       | log₂FC | FDR   | miRNA_ID       | log₂FC | FDR   |
|----------------|--------|-------|----------------|--------|-------|
| hsa-miR-876-5p | 13.31  | 0.01104 | hsa-let-7f-2-3p | 4.75   | 0.01169 |
| hsa-miR-3117-3p| 11.02  | 0.01191 | hsa-miR-495-3p  | 4.62   | 0.00587 |
| hsa-miR-655-3p | 10.93  | 0.00220 | hsa-miR-450a-5p | 4.61   | 0.01676 |
| hsa-miR-215-5p | 10.83  | 0.00271 | hsa-miR-656-3p  | 4.54   | 0.01232 |
| hsa-miR-25-5p  | 10.19  | 0.03121 | hsa-miR-101-3p  | 4.51   | 0.00866 |
| hsa-miR-153-5p | 10.06  | 0.01678 | hsa-miR-411-5p  | 4.51   | 0.02650 |
| hsa-miR-377-3p | 8.75   | 0.02109 | hsa-miR-142-3p  | 4.49   | 0.04022 |
| hsa-miR-495-5p | 8.64   | 0.02699 | hsa-miR-7-1-3p  | 4.44   | 0.04325 |
| hsa-miR-490-3p | 7.76   | 0.04137 | hsa-miR-98-3p   | 4.42   | 0.02650 |
| hsa-miR-218-5p | 6.14   | 0.01242 | hsa-miR-1197    | 4.42   | 0.01817 |
| hsa-miR-369-3p | 6.07   | 0.00372 | hsa-miR-127-5p  | 4.31   | 0.01817 |
| hsa-miR-21-5p  | 6.06   | 0.01817 | hsa-miR-590-3p  | 4.23   | 0.01893 |
| hsa-miR-9-3p   | 5.88   | 0.03226 | hsa-miR-3613-5p | 4.23   | 0.03121 |
| hsa-miR-7-5p   | 5.75   | 0.00231 | hsa-miR-136-3p  | 4.22   | 0.01676 |
| hsa-miR-218-2-3p| 5.67  | 0.03121 | hsa-miR-192-5p  | 4.09   | 0.03226 |
| hsa-miR-873-5p | 5.58   | 0.02699 | hsa-miR-424-5p  | 4.04   | 0.02701 |
| hsa-miR-19a-3p | 5.52   | 0.03767 | hsa-miR-454-3p  | 3.99   | 0.03238 |
| hsa-miR-32-5p  | 5.38   | 0.01518 | hsa-miR-299-3p  | 3.97   | 0.03666 |
| hsa-miR-301a-3p| 5.35   | 0.02699 | hsa-miR-590-5p  | 3.83   | 0.03315 |
| hsa-miR-137    | 5.33   | 0.00499 | hsa-miR-154-3p  | 3.81   | 0.03767 |
| hsa-miR-153-3p | 5.24   | 0.01676 | hsa-miR-374a-5p | 3.44   | 0.03121 |
| hsa-miR-142-5p | 5.14   | 0.03121 | hsa-miR-30e-5p  | 3.32   | 0.03121 |
| hsa-miR-106b-5p| 5.10   | 0.04325 | hsa-miR-337-3p  | 3.31   | 0.04571 |
| hsa-miR-380-3p | 4.95   | 0.01749 |                   |        |       |

#### B, miRNA species expressed at lower levels in NBs (MNA and MNnA are collectively considered) vs. DRG

| miRNA_ID       | log₂FC | FDR   | miRNA_ID       | log₂FC | FDR   |
|----------------|--------|-------|----------------|--------|-------|
| hsa-miR-6079   | -6.33  | 1.19E-20 | hsa-miR-1307-3p | -2.91  | 0.00127 |
| hsa-let-7d-3p  | -6.30  | 9.76E-18 | hsa-miR-320e    | -2.81  | 0.00175 |
| hsa-miR-1247-5p| -5.36  | 3.79E-06 | hsa-miR-193b-5p | -2.77  | 0.00219 |
| hsa-miR-4301   | -5.31  | 1.41E-13 | hsa-miR-1180-3p | -2.76  | 0.00512 |
| hsa-miR-328-3p | -5.19  | 1.9E-11  | hsa-miR-1306-5p | -2.75  | 0.00271 |
| hsa-miR-6074   | -4.71  | 6.15E-09 | hsa-let-7b-5p  | -2.75  | 0.00200 |
| hsa-miR-193a-5p| -4.50  | 5.22E-09 | hsa-miR-204-5p  | -2.74  | 0.03416 |
| hsa-miR-874-3p | -4.38  | 3.46E-09 | hsa-miR-197-3p  | -2.69  | 0.00133 |
| hsa-miR-2277-3p| -4.31  | 5.28E-10 | hsa-miR-744-5p  | -2.69  | 0.00763 |
| hsa-miR-760    | -4.13  | 0.00001 | hsa-miR-3605-3p | -2.66  | 0.00118 |
| hsa-miR-504-5p | -4.02  | 0.00009 | hsa-miR-99b-3p  | -2.66  | 0.00286 |
| hsa-miR-532-3p | -3.89  | 0.00001 | hsa-miR-146b-3p | -2.62  | 0.00590 |
| hsa-miR-338-5p | -3.85  | 0.00053 | hsa-miR-3177-3p | -2.61  | 0.00487 |
| hsa-miR-2110   | -3.85  | 0.00000 | hsa-miR-211-5p  | -2.59  | 0.03315 |
| hsa-miR-193b-3p| -3.84  | 0.00003 | hsa-miR-149-5p  | -2.59  | 0.02363 |
| hsa-miR-3974   | -3.76  | 0.00001 | hsa-miR-6803-3p | -2.56  | 0.00175 |
| hsa-miR-3620-3p| -3.68  | 0.00000 | hsa-miR-133b    | -2.52  | 0.00722 |
| hsa-miR-574-3p | -3.66  | 0.00014 | hsa-miR-3940-3p | -2.52  | 0.01649 |
| hsa-miR-320b   | -3.61  | 0.00010 | hsa-miR-125a-5p | -2.50  | 0.00499 |
| hsa-miR-320a   | -3.61  | 0.00072 | hsa-miR-6511b-3p| -2.49  | 0.00883 |
| hsa-miR-3615   | -3.60  | 0.00000 | hsa-miR-671-3p  | -2.49  | 0.00512 |
MEGIORNI et al: MYCN-RELATED miRNAs IN NEUROBLASTOMA

8

tively considered) and DRG, after removing poorly expressed miRNAs. Of a total of 198 differentially expressed miRNAs in the dataset, 128 (64.6%) displayed statistically significant differential levels in NB tumours in comparison with DRG, after FDR correction. Notably, out of these 128, 47 miRNAs (36.7%) were expressed at higher levels in NBs (Table IIA), while 81 (63.3%) were expressed at lower levels (Table IIB).

Table II. Continued.

B. miRNA species expressed at lower levels in neuroblastomas (NBs) (MNA and MNnA are collectively considered) vs. DRG

| miRNA_ID    | log2FC | FDR     | miRNA_ID    | log2FC | FDR     |
|-------------|--------|---------|-------------|--------|---------|
| hsa-miR-23b-5p | -3.48  | 0.00009 | hsa-miR-324-3p | -2.46  | 0.01152 |
| hsa-miR-92b-3p | -3.48  | 0.00009 | hsa-miR-1270 | -2.46  | 0.00831 |
| hsa-miR-183-5p | -3.47  | 0.03136 | hsa-miR-320d | -2.43  | 0.00957 |
| hsa-miR-423-3p | -3.46  | 0.00002 | hsa-miR-6511a-3p | -2.38  | 0.00590 |
| hsa-miR-940 | -3.42  | 0.00005 | hsa-miR-92a-1-5p | -2.38  | 0.04931 |
| hsa-miR-1257 | -3.33  | 0.00118 | hsa-miR-1296-5p | -2.33  | 0.02650 |
| hsa-miR-4532 | -3.33  | 0.00002 | hsa-miR-3975 | -2.33  | 0.02850 |
| hsa-miR-589-5p | -3.19  | 0.00009 | hsa-miR-3178 | -2.31  | 0.03121 |
| hsa-miR-615-3p | -3.19  | 0.00372 | hsa-miR-1227-3p | -2.28  | 0.00936 |
| hsa-miR-210-5p | -3.19  | 0.00118 | hsa-miR-1226-3p | -2.27  | 0.02737 |
| hsa-miR-423-5p | -3.13  | 0.00015 | hsa-miR-326 | -2.27  | 0.03136 |
| hsa-miR-487a-5p | -3.11  | 0.00020 | hsa-miR-1281 | -2.25  | 0.01676 |
| hsa-miR-1343-3p | -3.07  | 0.00492 | hsa-miR-380-5p | -2.18  | 0.02911 |
| hsa-miR-133a-3p | -3.07  | 0.00092 | hsa-miR-4272 | -2.18  | 0.03136 |
| hsa-miR-4787-3p | -3.03  | 0.00219 | hsa-miR-203a-3p | -2.17  | 0.03985 |
| hsa-miR-320c | -3.02  | 0.00071 | hsa-miR-4516 | -2.10  | 0.03315 |
| hsa-miR-483-5p | -2.99  | 0.03136 | hsa-miR-431-3p | -2.03  | 0.03862 |
| hsa-miR-874-5p | -2.95  | 0.00200 | hsa-miR-4429 | -2.00  | 0.03416 |
| hsa-miR-455-3p | -2.94  | 0.00111 | hsa-miR-1229-3p | -1.94  | 0.03066 |
| hsa-miR-769-3p | -2.93  | 0.00123 |

FDR, false discovery rate; FC, fold-change. NB, neuroblastoma; DRG, dorsal root ganglia.

Figure 2. (A) The overlap of known expressed miRNAs (with at least 10 read counts) in a given biological condition. Neuroblastoma (NB) tumours are in dark grey colour, while DRG controls are in white. (B) Fold-change plot of miRNA levels in the NB (MNA and MNnA collectively considered) vs. DRG comparison. x-axis, average log of counts per millions; y-axis, log2 fold-change (FC). miRNAs that are differentially expressed with P<0.05 are marked as a red dot.
oligometastases through suppression of shared target genes involved in cytoskeletal organization, cell motility and TGF-β signalling pathways (40). Also the marked downregulation of miR-328-3p in NB samples in comparison to DRG suggests its possible role as a tumour suppressor also in this malignancy as already observed in other types of cancers, such as acute myeloid leukaemia, chronic myelogenous leukaemia and glioblastoma (41,42). Therefore, future experiments will address the role of this miRNA in the proliferation, invasion and metastasis of NB tumour cells. Another new attractive result is the significant downregulation of miR-1247-5p, whose suppression has been demonstrated to play an important role in pancreatic cancer (43,44). Notably, the molecular mechanisms underlying the role of miR-1247-5p have been correlated with its capacity to directly target and silence the expression of neuropilins (44), which are transmembrane glycoproteins recently implicated in tumour functions and found as promising drug target candidates in leukaemia and lymphoma (45). Furthermore, miR-1247-5p also belongs to the 14q32 miRNA cluster (but in reverse strand in respect to the above mentioned miR-127-5p, miR-369-3p and miR-655-3p) and its aberrant expression in colorectal cancer has been linked to hypermethylation, confirming the importance of epigenetic modifications in miRNA-mediated cancer development (46). Since alterations in DNA methylation are frequent in NB and

| KEGG pathway                      | No of genes | FDR       |
|-----------------------------------|-------------|-----------|
| hsa05200:Pathways in cancer       | 70          | 1.92E-29  |
| hsa05212:Pancreatic cancer        | 27          | 1.58E-15  |
| hsa05222:Small cell lung cancer   | 28          | 1.05E-14  |
| hsa05215:Prostate cancer          | 28          | 5.60E-14  |
| hsa05210:Colorectal cancer        | 26          | 1.51E-12  |
| hsa05218:Melanoma                 | 23          | 3.46E-11  |
| hsa05220:Chronic myeloid leukaemia| 23          | 1.24E-10  |
| hsa05214:Glioma                   | 20          | 3.72E-09  |
| hsa04110:Cell cycle               | 27          | 4.45E-09  |
| hsa04010:MAPK signalling pathway  | 39          | 9.24E-09  |
| hsa04510:Focal adhesion           | 33          | 2.52E-08  |
| hsa04210:Apoptosis                | 21          | 2.36E-07  |
| hsa04115:p53 signalling pathway   | 18          | 1.42E-06  |
| hsa05211:Renal cell carcinoma     | 18          | 2.31E-06  |
| hsa05221:Acute myeloid leukaemia  | 16          | 8.40E-06  |
| hsa04620:Toll-like receptor signalling pathway | 20 | 2.42E-05 |
| hsa05223:Non-small cell lung cancer | 15        | 2.62E-05  |
| hsa05219:Bladder cancer           | 13          | 8.39E-05  |
| hsa05213:Endometrial cancer       | 14          | 1.36E-04  |
| hsa04722:Neurotrophin signalling pathway | 21 | 1.51E-04 |
| hsa04012:ErbB signalling pathway  | 16          | 0.002529  |
| hsa04520:Apoptosis                | 15          | 0.002890  |
| hsa04350:TGF-β signalling pathway | 15          | 0.012845  |
| hsa04930:Type II diabetes mellitus| 11          | 0.019442  |
| hsa04062:Chemokine signalling pathway | 22        | 0.030059  |

Comparison NB vs. DRG. Pathways significantly enriched are reported (FDR <0.05). FDR, false discovery rate; NB, neuroblastoma; DRG, dorsal root ganglia.

| KEGG pathway                      | No of genes | FDR       |
|-----------------------------------|-------------|-----------|
| hsa05200:Pathways in cancer       | 66          | 4.11E-30  |
| hsa05215:Prostate cancer          | 31          | 3.56E-19  |
| hsa05210:Colorectal cancer        | 29          | 1.40E-17  |
| hsa05212:Pancreatic cancer        | 26          | 6.02E-16  |
| hsa05220:Chronic myeloid leukaemia| 26          | 1.88E-15  |
| hsa05218:Melanoma                 | 24          | 1.33E-13  |
| hsa05221:Non-small cell lung cancer | 24        | 7.66E-13  |
| hsa05219:Bladder cancer           | 18          | 1.82E-11  |
| hsa05214:Glioma                   | 21          | 1.91E-11  |
| hsa05213:Endometrial cancer       | 19          | 7.55E-11  |
| hsa05223:Non-small cell lung cancer | 19        | 1.61E-10  |
| hsa05211:Renal cell carcinoma     | 20          | 2.15E-09  |
| hsa04722:Neurotrophin signalling pathway | 25 | 6.68E-09 |
| hsa04510:Focal adhesion           | 31          | 3.17E-08  |
| hsa04110:Cell cycle               | 24          | 5.71E-08  |
| hsa05222:Small cell lung cancer   | 20          | 7.21E-08  |
| hsa04370:VEGF signalling pathway  | 18          | 7.50E-07  |
| hsa04012:ErbB signalling pathway  | 19          | 1.13E-06  |
| hsa04310:Wnt signalling pathway   | 24          | 2.90E-06  |
| hsa04010:MAPK signalling pathway  | 31          | 1.62E-05  |
| hsa05216:Thyroid cancer           | 11          | 3.64E-05  |
| hsa04115:p53 signalling pathway   | 15          | 9.64E-05  |
| hsa05221:Acute myeloid leukaemia  | 14          | 9.79E-05  |
| hsa04660:T cell receptor signalling pathway | 18 | 2.45E-04 |
| hsa04662:B cell receptor signalling pathway | 15 | 3.51E-04 |
| hsa04350:TGF-β signalling pathway | 16          | 3.89E-04  |
| hsa04360:Axon guidance            | 19          | 6.88E-04  |
| hsa04320:Dorso-ventral axis formation | 9          | 0.001784  |
| hsa04914:Progesterone oocyte maturation | 15 | 0.002008 |
| hsa04916:Melanogenesis            | 15          | 0.011147  |
| hsa04620:Toll-like receptor signalling pathway | 15 | 0.014125 |
| hsa04630:Jak-STAT signalling pathway | 18 | 0.039146 |
| hsa04912:GnRH (gonadotropin-releasing hormone) signalling pathway | 14 | 0.047092 |

Comparison NB vs. DRG. Pathways significantly enriched are reported (FDR <0.05). FDR, false discovery rate; NB, neuroblastoma; DRG, dorsal root ganglia.
can also modulate sensitivity to cytotoxic agents (47), the analysis of the miR-1247-5p promoter region in NB samples could provide new insight into the mechanisms that correlate epigenetic processes and NB development.

To investigate the biological implications of the dysregulated miRNAs, we assessed miRNA target genes within the regulatory network for enrichment in Gene Ontology (GO), one of the most useful methods for functional annotation and classification of gene products. GO categories of the targets of the differentially upregulated and downregulated miRNAs (NB vs. DRG) were organized into three different functional groups, i.e. Biological process, Cellular component and Molecular function (Fig. 3), among which a significant over-representation of transcription factor activity/binding, protein kinase activity, chromatin modifications, metabolic processes, cell communication, plasma membrane, cytoplasm/intracellular organelle part, cell proliferation and programmed cell death regulation were found. To further explore the biological pathways potentially affected in NB development, targets of the differentially upregulated and downregulated miRNAs (NB vs. DRG) were organized into three different functional groups, i.e. Biological process, Cellular component and Molecular function (Fig. 3), among which a significant over-representation of transcription factor activity/binding, protein kinase activity, chromatin modifications, metabolic processes, cell communication, plasma membrane, cytoplasm/intracellular organelle part, cell proliferation and programmed cell death regulation were found. To further explore the biological pathways potentially affected in NB development, targets of the differentially upregulated and downregulated miRNAs (NB vs. DRG) were subjected to KEGG pathway analysis. Several cancer-related networks, including TGF-β, neurotrophin, MAPK, ErbB, Toll-like receptor and p53 signalling pathways, were significantly enriched (Tables III-IV). Indeed, the expression levels of TGFβR2, SMAD2 and SMAD4, three important components along the TGF-β cascade, were found to be downregulated in NB cells (48). VEGF, Wnt, JAK-STAT and GnRH pathways were found among the targets of the underexpressed miRNAs in accordance with their growth-inhibitory potential on NB (49-51). Moreover, some biological processes linked to cell cycle, adherents junction and focal adhesion could have also been altered. KEGG database interrogation also suggested that many of the miRNA targets contribute to the development of other human tumours, including colorectal, pancreatic cancer, melanoma and gliomas.

Differential expression analysis of miRNAs in NB with or without MYCN amplification. The miRNA expression profiles of MNA and MNnA tumours largely overlapped as shown by a Venn diagram (Fig. 4A), suggesting that only a small number of miRNAs are specific for each subgroup. After removing poorly expressed miRNAs, 70 molecules were found to be differentially expressed between MNA and MNnA tumours. Of these, 23 had a P<0.05 after FDR correction: 17 miRNAs were significantly upregulated in MNA samples, while 6 miRNAs were significantly downregulated (Table V). The most homogeneously expressed molecules among different tumours inside each subgroup were miR-16-2-3p, miR-18a-5p, miR-217, miR-301b-3p, miR-92a-3p, miR-935, miR-20a-3p, miR-628-3p, miR-628-5p and miR-3065-3p (data not shown). Among these, miR-18a-5p, miR-217, miR-491-5p and miR-628-3p were selected as candidates to validate the miRNA expression data

| miRNA       | log2FC | FDR      | Status       | Refs. | MYCN-binding motif |
|-------------|--------|----------|--------------|-------|--------------------|
| miR-517b-3p | 7.40   | 0.01263  | Upregulated  | Novel in NB | 0                  |
| miR-183-5p  | 4.07   | 0.01311  | Upregulated  | (52)  | 0                  |
| miR-182-5p  | 3.93   | 0.01263  | Upregulated  | (53)  | 0                  |
| miR-451a    | 3.45   | 0.01851  | Upregulated  | (61)  | 0                  |
| miR-217     | 3.29   | 0.00962  | Upregulated  | Novel in NB | 0                |
| miR-18b-5p  | 3.18   | 0.01137  | Upregulated  | (18)  | 2                  |
| miR-3182    | 2.85   | 0.02742  | Upregulated  | Novel in NB | 0                |
| miR-105-5p  | 2.84   | 0.03751  | Upregulated  | (62)  | 0                  |
| miR-20a-5p  | 2.80   | 0.01263  | Upregulated  | (18,48,62,63,74) | 1           |
| miR-130b-3p | 2.79   | 0.01263  | Upregulated  | (61)  | 0                  |
| miR-935     | 2.69   | 0.02807  | Upregulated  | (62)  | 0                  |
| miR-18a-5p  | 2.64   | 0.01263  | Upregulated  | (56,62,63,74) | 1              |
| miR-130b-5p | 2.64   | 0.01440  | Upregulated  | Novel in NB | 0                |
| miR-17-5p   | 2.57   | 0.01851  | Upregulated  | (18,48,55,62) | 1              |
| miR-301b-3p | 2.44   | 0.03073  | Upregulated  | Novel in NB | 0                |
| miR-16-2-3p | 2.38   | 0.01263  | Upregulated  | Novel in NB | 0                |
| miR-92a-3p  | 2.12   | 0.04003  | Upregulated  | (18,55,62,63,76) | 1           |
| miR-489-3p  | -3.25  | 0.01263  | Downregulated| Novel in NB | 2                  |
| miR-628-5p  | -2.53  | 0.01137  | Downregulated| (62,63) | 0                  |
| miR-338-5p  | -2.40  | 0.01263  | Downregulated| Novel in NB | 1                  |
| miR-491-5p  | -2.23  | 0.01263  | Downregulated| (76)   | 0                  |
| miR-628-3p  | -2.16  | 0.01851  | Downregulated| (18,48,62,63) | 1              |
| miR-3065-3p | -2.10  | 0.03073  | Downregulated| Novel in NB | 1                  |

FDR, false discovery rate; FC, fold-change; NB, neuroblastoma.
Figure 3. Gene Ontology (GO) analysis of miRNA target genes according to Biological process, Cellular component and Molecular function. (A) GO categories for the predicted gene targets of the upregulated miRNAs in the NB vs. DRG comparison. (B) GO categories for the predicted gene targets of the downregulated miRNAs in the NB vs. DRG comparison. All the categories were significantly enriched (FDR <0.05). FDR, false discovery rate; DRG, dorsal root ganglia; NB, neuroblastoma.
by qPCR experiments in the 8 deep-sequencing-analysed NB tumours and in 14 additional NB samples as well as in 4 human NB cell lines (MNA LAN5 and KCNR and MNNa SH-SY5Y and SK-N-SH). qPCR demonstrated that the expression levels of the selected dysregulated miRNAs showed strong overlap with the deep-sequencing findings, thus confirming the overexpression of miR-18a-5p and miR-217 as well as the downregulation of miR-491-5p and miR-628-3p in MNA (n=11) in comparison to MNNa (n=11) NB cases. Histograms indicate the mean value ± SD of independent tumours (P<0.05). MNA, MYCN-amplified; MNNa, MYCN-non amplified.

Figure 4. (A) Distribution of different miRNAs with at least 10 read counts in a given biological condition. MYCN-non amplified tumours are in dark grey, while MYCN-amplified tumours are in white. (B) Validation of miRNA array data by quantitative real-time polymerase chain reaction (qPCR). Relative expression levels for miR-18a-5p, miR-217, miR-491-5p and miR-628-3p in MNA (n=11) in comparison to MNNa (n=11) NB cases. Histograms indicate the mean value ± SD of independent samples. MNA, MYCN-amplified; MNNa, MYCN-non amplified.

Figure 5. (A) Schematic representation of the luciferase construct with a fragment of 880 bp of the MYCN 3’UTR, including the predicted target sequence for miR-628-3p. (B) Luciferase activity in HEK293T cells overexpressing miR-628-3p and the MYCN-3’UTR vector relative to cells transfected with miR-Ctr. Bars represent the mean of two independent experiments ± SD, each carried out in triplicate. (P<0.01). (C) Reduction of MYCN protein levels in KCNR cells transiently transfected with miR-628-3p mimics in comparison to miR-Ctr samples. Tubulin was used as loading control. Representative image from three independent experiments. The intensity of the MYCN bands was evaluated by densitometric analysis, normalized to the tubulin signal, and reported with respect to untreated cells (miR-Ctr).
Table VI. Predicted targets of overexpressed miRNAs, involved in DNA repair, apoptotic signalling pathway, FGF receptor signalling pathway, axon guidance and negative regulation of adenylyl cyclase activity.

| miRNA   | Target genes                                      |
|---------|---------------------------------------------------|
| miR-16-2-3p | AATK, ATP2A2, BCL2, BNIP2, BRCA1, CASP10, CNOT7, FANCE, FANCF, FRS2, GALR1, GNA13, IL16, KCNN3, KLRD1, MAPK8, MDM2, PRKX, PTGER3, RAD51C, RICTOR, RPS6KA5, SCN7A, SLCA8A1, SMAD2, SOS1, SRGAP1, STX7, WASF3, ZNF83 |
| miR-18a-5p | ACAP2, ACTR3, ADRBK2, ANGPT2, ATP2A2, BNIP2, CABLES1, CA2CA2D2, CACNB3, CASP10, CASP2, CCNK, CCR2, CD47, CD59, CDK2, CDK5R1, CHRM2, CITTA, CNOT7, CTDSPL, DAB1, DFFA, DFFB, EIF3A2, EPHAS, ESR1, FANCI, FRS2, FZD4, GNA13, GNB5, GRM1, GRM4, HEBP1, HIPK2, HOMER2, INSR, ITGA2, KCNN3, KIF3B, KIF5A, KLRD1, LCK, MAPK8, MAVS, MDM2, MMS22L, MYLK, NEO1, NEURL1B, NOTCH2, NTRK2, OPRL1, OTUD7B, PCSK2, PDGFRB, PRKX, RAD51B, RAD51C, RAIPA1, RPS6KA5, SH3KBP1, SLCA6A2, SMAD2, SOS1, SRGAP1, TNFSF12, TUBB3, WASF3, WHSC1, WNT9A, WWT1 |
| miR-217   | ACAP2, ADAM12, ADRBK2, ARHGFE7, BARD1, BCL2, BNIP2, BTC, CD59, CFLAR, CHTA, CNOT6L, CNOT7, COL21A1, CREBS, DAB1, DMRTB1, DOCK4, DYNLL2, DYRK1A, EPHAS, ERC1, FG16, FZD4, GALR1, GFRA1, GNA13, HOMER2, HOXD8, HSD17B2, IL16, ITGA2, ITGA9, KCNN3, MAP1B, MAPK4K, Mavs, MCM8, MDM2, MMS22L, MSH6, MYLK, NOTCH2, NTRK2, OSBPL1A, OTUD7B, PDCD1, PFDN1, PRKCA, PRKX, RASGRF3, RG56, RICTOR, ROBO2, RPS6KA5, SCN7A, SIPA1L2, SLCA8A1, SLX4, SMAD2, SMAD9, SOS1, STX1A, STX7, STXB2P5, TG, TMBIM4, TNFSF10, USF1, WHSC1, ZNF224, ZNF605 |

as previously reported (55,56) and in line with the evidence that MYCN directly activates miR-17-92 expression in NB cell lines (55). Indeed, the miR-17-92 cluster has a unique promoter control region and encodes for a precursor transcript that contains six tandem-loop hairpin structures, which in turn produce the six mature molecules miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92a-1 (57,58). These miRNAs may act independently or synergistically to target multiple mRNAs encoding for proteins implicated in cancer-related pathways (57,58). Given the miR-17-92 oncogenic role, inhibition of the clustered oncomiRs by delivering single-stranded antisense oligonucleotides (59) may represent a novel and attractive treatment approach for NB therapy. Regarding this aspect, Fontana et al (60) demonstrated that in vitro and in vivo treatment of MNA NB cells with a specific antagonimiR against miR-17-5p was able to dramatically reduce proliferation and to activate massive apoptosis through p21 and BIM over-expression, respectively. Concerning some downregulated miRNAs in MNA tumours, our data are in agreement with recently published studies. In particular, miR-491-5p was found to be significantly downregulated at NB metastatic sites compared with primary tumours by Guo et al (61), and miR-628 was confirmed to be moderately expressed in favourable NBs and nearly absent in unfavourable cases, thus, supporting its tumour-suppressive function and its potential as a good candidate in discriminating between these two NB subsets (38,62,63). Indeed, among the downregulated miRNAs, miR-628-3p has one pairing region at position 718-724 of the MYCN 3' untranslated region (3'UTR; Fig. 5A), as predicted by Miranda software (best score ≥120). To verify whether miR-628-3p was able to directly target MYCN mRNA, HEK293T cells were co-transfected either with a reporter construct containing 880 base pairs of the human MYCN 3'UTR downstream of the Renilla luciferase open reading frame.
frame (Fig. 5A) with either miR-628-3p mimic or negative control miRNA (miR-Ctr). Overexpression of miR-628-3p upon transfection was confirmed by qPCR assays (data not shown). Luciferase activity was specifically reduced to ~35% ($P<0.01$) in cells transfected with miR-628-3p compared to the control group (Fig. 5B), thus indicating that miR-628-3p functionally interacts with the MYCN 3’UTR and decreases the expression of the corresponding protein. Indeed, miR-628-3p mimics transiently introduced into kCNR cells, an in vitro model of MNA NB, were able to slightly reduce endogenous MYCN protein levels as compared with miR-Ctr positive samples (Fig. 5C), suggesting a functional role of miR-628-3p in MYCN gene expression. Finally, our analysis identified a set of differentially expressed miRNAs, such as miR-130b-5p, miR-217, miR-3065-3p, miR-3182, known as oncomiRs in several other tumours (64-67), but whose role in NB has not yet been investigated (Table V). Notably, miR-130b and miR-301b belong to the same genomic cluster located on chromosome 22 and are significantly upregulated in triple-negative (lacking the expression of the oestrogen receptor, the progesterone receptor and the human epidermal growth factor receptor 2) breast cancer (64), having a direct role in cyclin G2 regulation. miR-338 and miR-3065 belong to the brain-specific genomic cluster located on chromosome 17 in an intronic region within the apoptosis-associated tyrosine kinase (AATk) gene, thus having a tumour-suppressor function (68). Accordingly, it was described that miR-338-3p strand has the potential to inhibit cell proliferation, cell migration and invasion in human NB cells by affecting the PTEN/Akt pathway (69). miR-3065 was recently mapped to the antisense strand of miR-338 (70) and regarded as a novel promising candidate contributing to clear cell renal cell development (71). Furthermore, our miRNA promoter in silico analysis showed that downregulated miR-338-5p, miR-489-3p, miR-628-3p and miR-3065-3p in the MNA vs. MNnA comparison. Diamond-shaped nodes represent transcription factors; round-shaped nodes represent genes; solid lines indicate direct interactions; dashed lines represent indirect relationship.

Figure 7. Main functional module by GO Biological Process Enrichment Analysis of Functional Interaction Networks from target genes of downregulated microRNAs (miR-338-5p, miR-489-3p, miR-491-5p, miR-628-3p, miR-628-5p and miR-3065-3p) in the MNA vs. MNnA comparison.
miRNA | Target genes
--- | ---
miR-338-5p | Bnip2, C5ar1, CD28, Clock, Cn1, Creb1, CX3Cr1, Dgk1, Dsc2, Elk4, Enah, Eph, Ephn1, Gnb5, Grin2b, Impad1, Inpp4B, Insr, Kcnj15, Kcnj6, Kras, Lepr, Mapk1, Mapk2, Mapk3, Mapt, Mb, Mylk, Nf2, Pgr, Pkn2, Ppar-gc1a, Prkc, Pska5, Sntb1, Stt2r, Ugt8, Unc5c
miR-489-3p | Abl2, Abml3, Adcy6, Atp6ap1, Cacna1b, Cacna1d, Cacng8, Cds2, Cflar, Clock, Creb1, Creb5, Crkl, Dbnl, Dgk1, Dusp4, Elk4, Ephn1, Gna11, Gna15, Gnb5, Grb10, Gria4, Grk2, Grin2b, Hnf4g, Igf1r, Kcnj15, Kcnj6, Krld1, Map2k1, Map3k2, Mapk1, Mapk14, Mef2a, Mylk, Myo10, Nfat5, Nkba1, Ntrk3, Pak3, Paqr5, Pde3a, Phlpp2, Pik3c3, Pkpn1, Plxn4a, Ppp2r2c, Ptgfr, Ptpn23, Ralgapa2, Rapgef3, Rasgrf1, Rps6ka5, Scn4b, Sem6a, Shc4, Sirpa, Snx17, Stt2r, Tank, Tnk1, Unc5c
miR-491-5p | Adcy1, Adcy5, Akt2, Batf2, Cacna1c, Cacna2d1, Camk2b, Ccnk, Cds2, Cflar, Creb1, Creb3l2, Crkl, Crtc2, Cx3cr1, Dbnl, Dedd, Dgkg, Disc1, Dock5, Dsc2, Dusp4, Dusp7, Dusp8, Efs, Elmsan1, Ephn1, Eps15l1, Fgfr3, Fosb, Gab3, Gabbr1, Gabbr1, Galr1, Glpl2r, Gna11, Gna01, Gng7, Gpr132, Grik4, Hla-a, Hnf1a, Il6, Inpp4b, Inpp5e, Igf2r, Kcnj12, Kras, Mapk1, Mbp, Med15, Med17, Med24, Mef2d, Mylk, Nmt1, Ntrk3, Pagi, Pqar5, Pek1, Pgr, Pj4k2a, Plxn4a, Pou2f2, Prkcb, Ptpn23, Ralgapa2, Rapgef3, Rasdi1, Rgs11, Rgs19, Rin3, Roc1, Rs6ka2, Rs6ka5, Rusc1, Srpr1, Sar1, Sem6a, Sh3gl1, Sirpa, Snx17, Sp1b, Sqtst1, Stt2r, Stt5, Stat6, Traf3, Tshr, Vipr1, Znf76
miR-628-3p | Abl2, Abara, Cacna2d1, Chrna7, Creb3l2, Cxcl12, Cxcr2, Dgk1, Dsc2, Dsp, Dusp16, Enah, Eps15l1, Gria3, Grik4, Hlf, Igf1r, Impad1, Irs1, Kcnj15, Kcnj6, Krld1, Kras, Mchr2, Pak3, Peak1, Pgr, Pias2, Plag1, Prkc, Ptk, Ret, Rs6ka5, Sar1, Sh3bp5
miR-628-5p | Abl2, Atpp6ap1, Cacna1c, Calm2, Camk2g, Cd72, Cflar, Chrnna7, Creb1, Dgkz, Dock5, Dsc2, Edn1, Enah, Fshb, Gmfb, Hnf4g, Igf1r, Ile16, Il1r1, Il4r, Inpp4a, Igf2r, Kcnj6, Mapk1, Med24, Myo18a, Ntrk3, Pagi, Pak3, Pccb, Peak1, Pgr, Pp1r3d, Ralgapa2, Ret, S6ka4, Slt2a1, Tcf4, Traf3, Vldlr, Wnt2b, Yy1ap1
miR-3065-3p | Abl2, Ahnak, Arc, Atg9a, Baitap2, Batf2, Bdnf, Bid, Cd40, Cd59, Ch2d2, Chrnna7, Citta, Clock, Creb1, Creb5, Crmp1, Crtc3, Dapk1, Abl2, Ahnak, Arc, Atg9a, Baitap2, Batf2, Bdnf, Bid, Cd40, Cd59, Ch2d2, Chrnna7, Citta, Clock, Creb1, Creb5, Crmp1, Crtc3, Dapk1, Dmrt2, Dsc2, Dusp2a, Eaf2, Elk4, Elmsan1, Enah, Fadd, Fos, Fosb, Gabbr1, Gcdh, Gsdma, Hda-Doa, Hlf, Hnf1a, Il1r1, Krt8, Ldh, Maf, Mafb, Mapk4, Mapk10, Mapk11, Mapkapk2, Mapkapk3, Mbp, Med5, Med24, Medf2, Nfatc2, Nfatc3, Nfkbia, Per1, Pkp1, Pkp2, Plxn4a, Pou2f1, Pou2f2, Ptprh, Pska4k, Pska5, Sar1, Smpd3, Tab1, Tal1, Tbx21, Tnfrsf8, Tnip2, Tradd, Traf3, Traf6, Wasf2, Znf142

but also a mediator of transcriptional silencing by facilitating DNA methylation (54,72,73). Thus, it will be interesting to characterise the molecular mechanisms that regulate miRNA expression.

miRNA target prediction and functional annotation in NBs with or without MYCN amplification. Using the miRtarBase web tool, we found a relevant number of cancer-related genes, such as Pten, Kras and EzH2 among the validated target genes for the differentially expressed miRNAs. Indeed, since the availability of experimentally validated targets in miRtarBase was variable and possibly biased towards the more extensively investigated miRNAs, we decided to extend our analysis and perform a de novo target prediction using the miRanda software. In particular, we considered miRNAs with a homogeneous expression level between tumours inside each group: upregulated miR-16-2-3p, miR-18a-5p, miR-217 and downregulated miR-338-5p, miR-489-3p, miR-491-5p, miR-628-5p, miR-628-5p and miR-3065-3p. The 3’UTR sequences of all human transcripts present in Ensembl were screened for the identification of putative microRNA binding sites: a total of 867 putative target genes were identified for the upregulated miRNAs, while 2148 target genes were identified as potentially modulated by the downregulated miRNAs. The
Table VIII. Main modules involved in the functional interaction network built with Cytoscape from the predicted target genes of the selected microRNAs.

| Enriched term          | DNA repair | FGF signalling pathway | Apoptotic signalling pathway | Axon guidance | Negative regulation of adenylate cyclase activity |
|------------------------|------------|------------------------|-----------------------------|---------------|-----------------------------------------------|
| Number of target genes annotated with this term | 10 | 5 | 5 | 6 | 4 |
| P-value | 0 | 1.90E+01 | 1.00E+00 | 1.30E+01 | <1.000e-03 |
| FDR | <1.000e-03 | BTC | CFLAR | ITGA2 | PRKCA |
| Gene list | RADS1C | RADS1B | FGF16 | TNFSF12 | CACNB3 |
|           | SLX4 | FANCI | LCK | TNFSF10 | RPS6KA5 |
|           | FANCE | FANCF | PDGFRB | CASP2 | ROBO2 |
|           | MSH6 | CDK2 | CFLAR | BRCA1 | PRKCB |
|           | BRCA1 | BARD1 | |
| FDR, false discovery rate | <1.000e-03 | | | | |

| Enriched term          | TLR signalling pathway | EGFR signalling pathway | Synaptic transmission |
|------------------------|------------------------|------------------------|-----------------------|
| Number of target genes annotated with this term | 18 | 13 | 27 |
| P-value | 0 | <1.000e-03 | <1.000e-03 |
| FDR | <2.000e-04 | | |
| Gene list | CREB1 | DUSP4 | DUSP7 | FADD | FOS |
|           | MAPK1 | MAPK10 | MAPK11 | MAPK14 | MAPKAPK2 |
|           | MAPKAPK3 | MEF2A | NFKBIA | RPS6KA2 | RPS6KA5 |
|           | SARM1 | TAB1 | TRAF3 | |
|           | |
| FDR, false discovery rate | <1.000e-03 | <1.000e-03 | <1.000e-03 |

The most highly enriched Gene Ontology Biological Process (GO BP) in each module with the corresponding P-value and FDR for the target genes of upregulated (A) and downregulated (B) miRNAs in the MNA vs. MNnA comparison. FDR, false discovery rate.
predicted targets were grouped into functional modules on the basis of their functional interactions, and for each module an enrichment analysis was performed with the Cytoscape Reactome FI plugin. Fig. 6 shows the main functional module putatively regulated by miR-16-2-3p, miR-18a-5p and miR-217, which are overexpressed in MNA tumours. The different interaction networks are enriched in gene products implicated in cancer-related biological processes, such as DNA-repair and apoptosis, as well as axon guidance, adenylate cyclase activity and the FGFR signalling pathway. Target genes associated to each specific overexpressed miRNA are reported in Table VI. The GO categories associated with the predicted miRNA targets showed significant overlap with biological processes that are over-represented in the MYCN target genes (38), confirming the existence in NB of a miRNA:MYCN related network able to broadly perturb gene expression (38,74,75).

Fig. 7 shows the main functional module putatively regulated by miR-338-5p, miR-489-3p, miR-491-5p, miR-628-3p, miR-628-5p and miR-3065-3p which are underexpressed in MNA samples. The enriched interactions consist of proteins involved in synaptic transmission as well as TLR and EGFR signalling pathways. Target genes associated to each specific downregulated miRNA are reported in Table VII.

The complete list of network modules and GO BP - pathway

Figure 8. (A) Distribution of isomiRs and sequence variants in all examined tumours. (B) Secondary stem-looped structure of a putative novel miRNA significantly overexpressed in MNA cases. (C) Schematic representation of mTOR signalling pathway. Red characters represent key genes regulated by the predicted novel miRNA. MNA, MYCN-amplified.
enrichment is included in the Table VIII. Our results suggest that the selected differentially expressed miRNAs are relevant in NB biology and could be of potential importance to stratify high-risk and low-risk tumours. Further investigations will be necessary to validate the specific target genes and to assess the downstream effects.

IsomiRs and novel miRNAs. Recent findings identified a large number of sequences with different 5’ or 3’ flanking regions, called isomiRs (76). From a biological point of view, the most interesting isomiRs are the 5’-isomiRs (having different 5’-ends compared to their corresponding canonical miRNAs) as they are potentially able to recognize different targets with respect to the main isomir. A list of isomiRs (length and sequence variants) was generated from the miRDeep2 output with proprietary scripts, and their expression was evaluated in all samples. As expected, compared to the total number of isomiRs detected in our dataset, 5’-isomiRs were less frequent: out of 18,809 isomiRs with at least 10 read counts in at least one library, 3,769 were 5’-isomiRs (20%), as described in Fig. 8A. The presence of miRNA length variants suggests that these isomiRs might have different regulatory functions or efficiencies, this allowing a finely tuned control of global gene expression. Furthermore, in silico data analysis identified 18 putative novel miRNAs expressed in the tumour samples. Two of these were differentially expressed in MNA vs. MNA tumours. In particular, a hairpin with genomic coordinates chr4:180531388-180531451 was detected as significantly overexpressed in the MNA tumours (P<0.001; FDR=0.02) using the ‘GLM’ analysis, and it demonstrated a uniform expression within each biological subgroup. The secondary stem-loop structure of this putative novel miRNA is shown in Fig. 8B. According to the miRanda predictions, this candidate miRNA has ~900 putative targets, which are enriched in transcriptional regulation and protein phosphorylation ontology terms. Interestingly, a significant number of putative target genes, highlighted in red in Fig. 8C, are correlated with the mTOR signalling cascade, outlining the evidence for the aberrant activation of this pathway in NB (77-79). For this reason, the putative new miRNA may be an interesting candidate for future functional studies in order to determine its biological relevance in mTOR signalling, which in turn might lead to the identification of further molecular targets in NB tumour.

In conclusion, in the present study, NGS technology and bioinformatics analysis allowed the identification of a specific set of miRNAs that are differentially expressed in NB tumours compared to DRG, or in NB tumours with or without MYCN amplification. A relevant percentage of these microRNAs has been already found to be involved in NB, another percentage has been shown to be involved in the pathogenesis/progression of other tumours, while other miRNAs are new. Target prediction and functional annotation highlighted the possible roles of the identified microRNAs, and in vitro assays provide initial evidence of the contribution of miR-628-3p to MYCN regulation. New potential miRNA candidates not previously reported were also found, but further studies are needed to clarify their role in NB development.

Altogether, these findings may provide further insight concerning NB development and may also contribute to the identification of novel potential therapeutic targets in this highly lethal childhood tumour.

Acknowledgements
The present study was supported by the ‘Associazione Onlus Fabrizio Proccaccini’, ‘IO, domani...Associazione Onlus per la Lotta contro i Tumori Infantili’ (ALTI), ‘Isle of Man Anti-Cancer Association’, Italian ‘Ministero dell’Istruzione, dell’Università e della Ricerca’ (MIUR) and Genomnia Srl R&D funds.

References
1. Irwin MS and Park JR: Neuroblastoma: Paradigm for precision medicine. Pediatr Clin North Am 62: 225-256, 2015.
2. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Ichihara T, Machin D, et al; INRG Task Force: The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J Clin Oncol 27: 289-297, 2009.
3. Maris JM: Recent advances in neuroblastoma. N Engl J Med 362: 2202-2211, 2010.
4. Friedeman M, Varmus HE, Bishop JM, Grzeschik KH, Naylor SL, Sakaguchi AY, Brodeur G and Trent J: Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc. Nature 308: 288-291, 1984.
5. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG and Bishop JM: Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16: 2985-2995, 1997.
6. Yoshimoto M, Caminada De Toledo SR, Monteiro Caran EM, de Seixas MT, de Martino Lee ML, de Campos Vieira Abib S, Vianna SM, Schettini ST and Anderson Duffles Andrade J: MYCN gene amplification. Identification of cell populations containing double minutes and homogeneously staining regions in neuroblastoma tumours. Am J Pathol 155: 1439-1443, 1999.
7. Guglielmi L, Cinnella C, Nardella M, Maresca G, Valenti A, Mercanti D, Felsiani A and D’Ag nanoparticles: MYCN gene amplification is required for the onset of the differentiation programme in neuroblastoma cells. Cell Death Dis 5: e1081, 2014.
8. Kaneko Y, Sueyama Y, Islam SM, Matsumoto D, Nakamura Y, Ohira M, Yoshioka S and Nakagawara A: Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas. Cancer Sci 106: 840-847, 2015.
9. Lau DT, Flemming CL, Gherardi S, Perini G, Oberlinger A, Fischer M, Juraeva D, Brors B, Xue C, Norris MD, et al: MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma. Oncotarget 6: 15510-15523, 2015.
10. Beltran H: The N-myc Oncogene: Maximizing its targets, regulation, and therapeutic potential. Mol Cancer Res 12: 815-822, 2014.
11. Zeng Y, Yi R and Cullen BR: MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci USA 100: 9779-9784, 2003.
12. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
13. He L and Hannon GJ: MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531, 2004.
14. Kozomara A and Griffiths-Jones S: miRBase: Integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 39 (Database): D152-D157, 2011.
15. Friedeman RC, Farh KK, Burge CB and Bartel DP: Most mammalian microRNAs are conserved targets of microRNAs. Genome Res 19: 92-105, 2009.
16. Domingo-Fernandez R, Watters K, Piskareva O, Stallings RL and Bishop JM: Targeted expression of MYCN causes neuroblastoma disease pathogenesis. Pediatr Surg Int 29: 101-119, 2013.
17. Leichter AL, Sullivan MJ, Eccles MR and Chaterjee A: MicroRNA expression patterns and signalling pathways in the development and progression of childhood solid tumours. Mol Cancer 16: 15, 2017.
18. Mei H, Lin ZY and Tong QS: The roles of microRNAs in neuroblastoma. World J Pediatr 10: 10-16, 2014.
19. Bray I, Tivnan A, Bryan K, Foley NH, Watters KM, Tracey L, Davidoff AM and Stallings RL: MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma. Cancer Let 303: 56-64, 2011.
20. Tivnan A, Tracey L, Buckley PG, Alcock LC, Davidoff AM and Stallings RL: MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. BMC Cancer 11: 33, 2011.
21. Chen Y, Tsai YH, Fang Y and Tseng SH: MicroRNA-21 regulates the sensitivity to cisplatin in human neuroblastoma cells. J Pediatr Surg 47: 1797-1805, 2012.

22. Ryan J, Tivnan A, Fay J, Bryan K, Meehan C, Ceeveey L, Lynch J, Bray JM, Hara A, Tracey L, et al.: MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. Br J Cancer 107: 967-976, 2012.

23. Telliet MA, Kalcheim C and Le Douarin NM: Formation of the dorsal root ganglia in the avian embryo. Segmental origin and migratory behavior of neural crest progenitor cells. Dev Biol 120: 329-347, 1987.

24. Beckwith JB and Martin RF: Observations on the histopathology of neuroblastomas. J Pediatr Surg 3: 106-110, 1968.

25. Griffiths-Jones S, Saimi HK, van Dongen S and Enright AJ: miRBase: tools for microRNA genomics. Nucleic Acids Res 36 (Database): D154-D158, 2008.

26. Robinson MD and Oshlick A: A scaling normalization method for differential expression analysis of mRNA-seq data. Genome Biol 11: R25, 2010.

27. Bullard JH, Purdom E, Hansen KD and Dudoit S: Evaluation of statistical methods for normalization and differential expression in mRNA-seq experiments. BMC Bioinformatics 11: 94, 2010.

28. Hsu SD, Tseng YT, Shrestha S, Lin YL, Khaleel A, Chou CH, Hsu WM, Lee WT and Lee H: Calreticulin regulates vEGF-A in neuroblastoma cells. Mol Neurobiol 52: 758-770, 2015.

29. Lodrini M, Oehme I, Schroeder C, Milde T, Schier MC, kopp-Asane S and Rajewsky N: Discovering microRNAs from deep sequencing data using miRTarBase. Nucleic Acids Res 42 (D1): D78-D85, 2014.

30. Murphy DM, Buckley PG, Bryan K, Das S, Alcock L, Foley NH, Premter S, Bray I, Watters KM, Higgins D, et al.: Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation. PLoS One 4: e8154, 2009.

31. Mestdagh P, Boström AK, Impens F, Fredlund E, van Peer G, de Antonellis P, von Stedingk K, Ghesquière B, Schulte S, Desmoulière V, et al.: The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma. Mol Cell 40: 762-773, 2010.

32. Anwar SL, Albat C, Krech T, Hasemeier B, Schipper E, Schwetzner N, Vogel A, Kreipe H and Lehmann U: Concordant hypomethylation of microRNA genes in human hepato-cellular carcinoma as new diagnostic and prognostic marker. Int J Cancer 133: 660-670, 2013.

33. Shi S, Lu Y, Qin Y, Li W, Cheng H, Xu Y, Xu J, Long J, Liu L, Liu C, et al.: miR-1247 is correlated with prognosis of pancreatic cancer and inhibits cell proliferation by targeting neuropilins. Curr Mol Med 14: 316-327, 2014.

34. Wang J, Huang Q, Xie J, Liu Z, Zhao L, Ye J, et al.: DNA methylation increases sensitivity of neuroblastoma cells to chemotherapeutic drugs. Biochem Pharmacol 83: 858-865, 2012.

35. Mestdagh P, Boström AK, Impens F, Fredlund E, de Antonellis P, von Stedingk K, Ghesquière B, Schulte S, Desmoulière V, et al.: The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma. Mol Cell 40: 762-773, 2010.
63. Rahmann S, Martin M, Schulte JH, Köster J, Marschall T and Schramm A: Identifying transcriptional miRNA biomarkers by integrating high-throughput sequencing and real-time PCR data. Methods 59: 154-163, 2013.

64. Chang YY, Kuo WH, Hung JH, Lee CY, Lee YH, Chang YC, Lin WC, Shen CY, Huang CS, Hsieh FJ, et al: Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing. Mol Cancer 14: 36, 2015.

65. Zhang Y, Hu Y, Fang YJ and Xu J: Gain-of-function miRNA signature by mutant p53 associates with poor cancer outcome. Oncotarget 7: 11056-11066, 2016.

66. Pehserl AM, Ress AL, Stanzer S, Resel M, Karbiener M, Stadelmeyer E, Stiegelbauer S, Gerger A, Mayr C, Scheideler M, et al: Comprehensive analysis of miRNome alterations in response to sorafenib treatment in colorectal cancer cells. Int J Mol Sci 17: E2011, 2016.

67. Wang H, Zhi H, Ma D and Li T: MiR-217 promoted the proliferation and invasion of glioblastoma by repressing YWHAG. Cytokine 92: 93-102, 2017.

68. A D, Olde Loohuis NF, Wieczorek ML, Glennon JC, Martens GJ, Kolk SM and Aschrafi A: A potential regulatory role for intronic microRNA-338-3p for its host gene encoding apoptosis-associated tyrosine kinase. PLoS One 7: e31022, 2012.

69. Chen X, Pan M, Han L, Lu H, Hao X and Dong Q: miR-338-3p suppresses neuroblastoma proliferation, invasion and migration through targeting PREX2a. FEBS Lett 587: 3729-3737, 2013.

70. Chiang HR, Schoenfeld LW, Ruby JG, Auveugne VC, Spies N, Baek D, Johnston WK, Russ C, Luo S, Babiarz JE, et al: Mammalian microRNAs: Experimental evaluation of novel and previously annotated genes. Genes Dev 24: 992-1009, 2010.

71. Müller S and Nowak K: Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles. BioMed Res Int 2014: 948408, 2014.

72. Murphy DM, Buckley PG, Das S, Watters KM, Bryan K and Stalling RL: Co-localization of the oncogenic transcription factor MYCN and the DNA methyl binding protein MeCP2 at genomic sites in neuroblastoma. PLoS One 6: e21436, 2011.

73. Čorveta D, Chayka O, Gherardi S, D’Acunto CW, Cantilena S, Valli E, Piotrowska I, Perini G and Sala A: Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: Functional and therapeutic implications. J Biol Chem 288: 8332-8341, 2013.

74. Buechner J and Einvik C: N-myc and noncoding RNAs in neuroblastoma. Mol Cancer Res 10: 1243-1253, 2012.

75. Jackstadt R and Hermeking H: MicroRNAs as regulators and mediators of c-MYC function. Biochim Biophys Acta 1849: 544-553, 2015.

76. Guo L and Chen F: A challenge for miRNA: Multiple isomiRs in miRNAomics. Gene 544: 1-7, 2014.

77. Iżycka-Świeszewska E, Drożyńska E, Rzepko R, Kobierska-Gulida G, Grajkowska W, Perek D and Balcerska A: Analysis of PI3K/AKT/mTOR signalling pathway in high risk neuroblastics tumours. Pol J Pathol 61: 192-198, 2010.

78. King D, Yeomanson D and Bryant HE: PI3King the lock: Targeting the PI3K/Akt/mTOR pathway as a novel therapeutic strategy in neuroblastoma. J Pediatr Hematol Oncol 37: 245-251, 2015.

79. Vaughan L, Clarke PA, Barker K, Chanthey Y, Gustafson CW, Tucker E, Renshaw J, Raynaud F, Li X, Burke R, et al: Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. Oncotarget 7: 57525-57544, 2016.